|
Requirements for NAs assessment in Russia
|
|
8
|
457
|
July 10, 2026
|
|
In Vitro Metabolism Study of NDSRIs
|
|
4
|
429
|
July 9, 2026
|
|
Deactivation feature on a 8-member ring with side chains?
|
|
7
|
228
|
July 9, 2026
|
|
Research on Nitrosamines in Complex Preparations
|
|
4
|
396
|
July 8, 2026
|
|
Another Prazosin recall linked to N-nitroso-prazosin impurity C raises renewed concern for the finished product
|
|
10
|
872
|
July 7, 2026
|
|
Peptide Synthesis - Does anyone have experience with potential Nitrosamine impurities coming from solid phase synthesis?
|
|
2
|
311
|
July 6, 2026
|
|
Risk Evaluation of N-Nitrosamines in Drug-Linker Intermediates Used To Generate Antibody–Drug Conjugates -Pub
|
|
3
|
468
|
July 6, 2026
|
|
N-nitroso-Furosemide
|
|
4
|
761
|
July 6, 2026
|
|
N-Nitroso Desethyl Amiodarone in Amiodarone HCl Tablets by LC-MS/MS Metodu
|
|
5
|
303
|
July 6, 2026
|
|
Analytical Challenges in Quantifier Ion Selection Due to Mass Error Variability
|
|
7
|
347
|
July 2, 2026
|
|
Nitrosamine limits in pediatric populations
|
|
4
|
280
|
June 30, 2026
|
|
Which carcinogenicity study should I use? Automated identification of reliable studies - PUB
|
|
0
|
114
|
June 29, 2026
|
|
🇺🇸 FDA FY26 GDUFA Public Workshop
|
|
21
|
1004
|
June 28, 2026
|
|
👨💻 Determination of nitrite and nitrate in pregelatinized starch by ion chromatography
|
|
0
|
239
|
June 26, 2026
|
|
Indian Pharmacopoeia introduces a new General Chapter on Nitrosamine Impurities in its 2022 edition
|
|
4
|
2073
|
June 26, 2026
|
|
Mutagenic Impurities in USP -future looking
|
|
17
|
1687
|
June 26, 2026
|
|
The Future of Bio/Pharmaceutical Analysis 2026 - Nitrosamines
|
|
4
|
337
|
June 26, 2026
|
|
Regulatory Flexibilities and Clarifications: Chemistry, Manufacturing and Control (CMC) Information for Original First in Human (FIH) Phase 1 INDs
|
|
2
|
370
|
June 25, 2026
|
|
NDSRI growth with respect to age
|
|
12
|
580
|
June 25, 2026
|
|
👨💻 Nitrosamines Conversations -Coming Soon! 🎙
|
|
0
|
146
|
June 25, 2026
|
|
Recrystallization can stop nitrosamine formation in ranitidine hydrochloride - PUB
|
|
1
|
263
|
June 24, 2026
|
|
NDBA interference on Parecoxib testing?
|
|
3
|
166
|
June 23, 2026
|
|
During analysis NDELA Area observed dropped in standard solution after running sample what could be the reason
|
|
1
|
96
|
June 23, 2026
|
|
A Robust and Universal LC–MS/MS Method for Determination of N-Nitrosodimethylamine in Pharmaceuticals Using a C30 Column -Pub
|
|
1
|
215
|
June 22, 2026
|
|
Nitrosamines & Genotoxic Impurities in Pharmaceutical Development and Manufacturing
|
|
3
|
402
|
June 21, 2026
|
|
Advancing Nitrosamine Analysis: USP Frameworks and LC-MS/MS Solutions
|
|
1
|
315
|
June 19, 2026
|
|
Why is NMEA associated with Amphotericin B? (Appendix 1 March 2026 Update)
|
|
3
|
300
|
June 19, 2026
|
|
Nitrosamine risk assessment in early clinical development
|
|
0
|
218
|
June 17, 2026
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
20
|
5670
|
June 17, 2026
|
|
Application of read-across to data-poor N-nitrosamines: N-nitroso-ulifloxacin, a case study-Pub
|
|
1
|
165
|
June 16, 2026
|